Condition: Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent · Sponsor: Prof. Dr. med. Ingo Eitel
In the proposed event driven trial, LAA closure devices will be compared in a 1:1 randomization to best medical care in AF patients at high risk of stroke and bleeding with ESKD. The trial will allow the use of the CE marked and clinically used LAA device Amplatzer Cardiac Plug and/or Amulet and all approved medical therapies in AF patients with ESKD including vitamin-K antagonists (VKA), NOACs as well as antiplatelet agents or no anticoagulation in excessive bleeding risk.
This description comes directly from the study's public registry record.
Ingo Eitel, MD · +49 451 500 44501 · ingo.eitel@uksh.de
Thomas Stiermaier, MD · +49 451 500 44501 · thomas.stiermaier@uksh.de
Always discuss trial participation with your own doctor first.
| Universität zu Lübeck | Lübeck, Schleswig-Holstein, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05204212